Similar Papers

Paper Title
Journal
Date
Author
Brain radiotherapy combined with camrelizumab and platinum-doublet chemotherapy for previously untreated advanced non-small-cell lung cancer with brain metastases (C-Brain): a multicentre, single-arm, phase 2 trial.
Yanjun Xu ... Yun Fan
The Lancet. Oncology | VOL. 26
Yanjun Xu, et. al.Yanjun Xu ... Yun Fan
01 Jan 2025
Tepotinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) with MET amplification (METamp).
Xiuning Le ... David Vicente Baz
Journal of Clinical Oncology | VOL. 39
Xiuning Le, et. al.Xiuning Le ... David Vicente Baz
20 May 2021
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial.
...
The Lancet Oncology | VOL. 23
, et. al. ...
01 Aug 2022
OA15.01 Mobocertinib in EGFR Exon 20 Insertion–Positive Metastatic NSCLC Patients With Disease Control on Prior EGFR TKI Therapy
...
Journal of Thoracic Oncology | VOL. 16
, et. al. ...
01 Oct 2021
View more papers

More From: The Lancet. Oncology

Paper Title
Journal
Date
Author
Decoding the genomic landscape of early-onset colorectal cancer: the next chapter in precision oncology.
Andreas Seeber
The Lancet. Oncology | VOL. -
Andreas SeeberAndreas Seeber
02 Jul 2025
Oral contraceptives and risk of liver cancer.
Lisa Iversen
The Lancet. Oncology | VOL. -
Lisa IversenLisa Iversen
02 Jul 2025
Patterns in genomic mutations among patients with early-onset colorectal cancer: an international, multicohort, observational study.
Jinming Li ... Yanlei Ma
The Lancet. Oncology | VOL. -
Jinming Li, et. al.Jinming Li ... Yanlei Ma
02 Jul 2025
First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta-Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study.
James P Buteau ... Michael S Hofman
The Lancet. Oncology | VOL. -
James P Buteau, et. al.James P Buteau ... Michael S Hofman
02 Jul 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.